H-E-B plans to offer COVID-19 vaccines once they're available. Photo courtesy of BCM

As a pair of COVID-19 vaccines await emergency-use approval from the U.S. Food and Drug Administration, Texas' largest grocer is prepping for the vaccines' unprecedented rollout.

San Antonio-based H-E-B announced its pharmacies will administer the COVID-19 vaccine to Texans once it's available to the general public.

"At H-E-B, the health and safety of Texans is our top priority," the company noted in a release posted December 3. "As a trusted source for all routine childhood and adult immunizations, H-E-B pharmacies will partner with the federal and state government to administer the COVID-19 vaccine when it becomes available to the general public, following the CDC distribution schedule."

Though it's unclear when H-E-B will receive the vaccine doses and which company's vaccine —Moderna, the Pfizer/BioNTech, or otherwise — will be available through the grocer, health-focused organizations and businesses like H-E-B are preparing for the massive distribution, which could begin as soon as 24 hours after the FDA gives its approval.

The goal of Operation Warp Speed, the federal government's plan to help develop, make, and distribute millions of COVID-19 vaccine doses to Americans, is "to deliver safe vaccines that work, with the first supply becoming available before the end of 2020," according to the Centers for Disease Control and Prevention.

The CDC also notes once a vaccine is approved and released, there may not be enough doses available for all U.S. adults, though supplies will increase over time and "all adults should be able to get vaccinated later in 2021."

The CDC further states that vaccine doses purchased with taxpayer money will be distributed to Americans for free. However, vaccine providers can charge an administration fee for providing the shot.

It's unclear how many doses each store will receive and whether the company plans to distribute the vaccine through its pharmacy drive-thrus, at onsite pop-up medical tents, or solely from its in-store pharmacies.

"We do have all H-E-B pharmacies registered and ready to administer the vaccine," says Leslie Sweet, H-E-B's director of public affairs in the Central Texas region. "We will follow the prescribed allocation schedule as prescribed by [the Department of State Health Services]. We do not yet have a specific date or allocation number to share."

H-E-B pharmacies throughout the state already have some safety measures in place because of COVID-19 concerns, including allowing customers to prepay for prescriptions on the phone prior to picking them up or have their prescriptions delivered for free, and offering no-contact pickup and delivery of prescriptions through its pharmacy drive-thrus.

Additionally, H-E-B says it is continuing to take steps to protect its customers and employees during the pandemic.

"We're going above and beyond our already stringent sanitation standards, cleaning and disinfecting pharmacy counters, waiting areas, and drive-thru surfaces at a higher frequency," the grocer notes in its recent release. "Our pharmacy partners are practicing proper hand-washing throughout the day, and disinfecting and wiping down commonly used surfaces. We've also installed acrylic barriers and provided masks and gloves for all pharmacy partners. … As always, your health and safety is of the utmost importance to us. Together, we can slow the spread."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.